0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessAdding low-dose rivaroxaban to aspirin resulted in benefits irrespective of the number of concomitant drugs or comorbidities. Multiple comorbidities and/or polypharmacy should not dissuade the addition of rivaroxaban to aspirin in otherwise eligible patients.
Thomas Vanassche, Peter Verhamme, Sonia S. Anand, Olga Shestakovska, Darryl P. Leong, Keith A.A. Fox, Deepak L. Bhatt, Álvaro Avezum, Marco Alings, Victor Aboyans, Aldo Maggioni, Petr Widimský, Eva Muehlhofer, Scott D. Berkowitz, Salim Yusuf, Stuart J. Connolly, John W. Eikelboom, Jackie Bosch (2021). Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. , 8(5), DOI: https://doi.org/10.1093/ehjcvp/pvab050.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2021
Authors
18
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.1093/ehjcvp/pvab050
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
